Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
B Cell Lymphoma|Lymphoma|Lymphoma, B-Cell|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma
DRUG: Pembrolizumab|DRUG: R-CHOP Protocol
Progression free survival (PFS) rate when combining pembrolizumab with R-CHOP, 24 months
Complete response (CR) rate after 6 cycles of pembrolizumab in combination with R-CHOP, 18 weeks|Event free survival (EFS) rate after 6 cycles of pembrolizumab in combination with R-CHOP, 18 weeks|Overall survival (OS) rate after 6 cycles of pembrolizumab in combination with R-CHOP, 18 weeks|Number of participants with treatment related adverse events as assessed by CTCAE v 4.0, Safety and tolerability of pembrolizumab in combination with R-CHOP followed by Pembrolizumab., 29 months
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.